Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement
Sara Oubari, Eyad Naser, Μαρία Παπαθανασίου, Peter Luedike, Tim Hagenacker, Andreas Thimm, Christoph Rischpler, Lukas Kessler, Christoph Kimmich, Ute Hegenbart, Stefan Schönland, Tienush Rassaf, Hans Christian Reinhardt, Karl‐Heinz Jöckel, Jan Dürig, Ulrich Dührsen, Alexander Carpinteiro
Abstract
Abstract Objective To study the impact of time to diagnosis on cardiac Mayo stages, treatment outcome, and overall survival. Methods We retrospectively analyzed 77 consecutive patients diagnosed between 2015 and 2020 with AL amyloidosis and cardiac involvement. Medical history was recorded in standardized form with the help of a questionnaire. Results Time from onset of symptoms of cardiac failure to diagnosis was correlated with the severity of cardiac involvement in modified Mayo 2004 and revised Mayo 2012 staging systems ( r s = 0.30, 95% CI: 0.07‐0.50, P = .007 and r s = 0.25, 95% CI: 0.01‐0.45, P = .03). Patients with advanced Mayo 2004 stages received reduced‐intensity regimens and had a lower probability to achieve adequate hematologic‐ and cardiac response after first‐line treatment than patients with early stages ( r s = 0.28, 95% CI: 0.04‐0.48, P = .01 and r s = 0.72, 95% CI: 0.55‐0.82, P < .0001) and poorer overall survival ( P = .0004). Compared with patients diagnosed within the first year, patients diagnosed after 13‐18 or ≥19 months from first symptoms had a 3‐ to 5 times higher risk of dying. Our data indicate that there is a 12‐month window within which the diagnosis of AL amyloidosis needs to be established to avoid early deterioration and death. Conclusions Sensitizing physicians and raising awareness for the disease are crucial for timely diagnosis and may improve the outcome of the disease.